Nasal encephaloceles: a review of etiology, pathophysiology, clinical presentations, diagnosis, treatment, and complications

Introduction

Encephaloceles are considered by most to be a type of neural tube defect characterized by a herniation of the brain and meninges through structural weaknesses in the bony structures of the skull.

Discussion

Many different types of encephaloceles have been classified according to the location of the bony defect. Basal and frontoethmoidal encephaloceles constitute a nasal subclass of encephaloceles, which are herniations from the skull base and ethmoid bone, respectively. Basal encephaloceles are usually occult and can herniate into nasal structures causing obstruction. Frontoethmoidal encephaloceles usually present as a protrusion that is visible at birth and enlarges during crying. Both of these entities are rare with an incidence ranging from 1 in 5,000 to 1 in 40,000 live births around the world with the majority of cases localized in Southeast Asia.

Conclusion

Although cases have been recorded since the sixteenth century, there is still a scarcity of knowledge on the exact causes and factors associated with the development of the disease. Many studies have determined these to be caused by a combination of genetic and environmental factors. Most cases are nonlife threatening and the preferred method of treatment is surgical removal after diagnosis is confirmed with computerized tomography or magnetic resonance imaging. Prognosis is generally positive, especially in the subset of patients with frontoethmoidal encephaloceles.     

Institutional experience of endoscopic suprasellar arachnoid cyst fenestration

Introduction

Suprasellar arachnoid cysts can differ from other arachnoid cysts in several ways, making a separate analysis of these cysts worthwhile. Herein, we present the outcome and perform volumetric analysis of six children with suprasellar arachnoid cysts treated with endoscopic ventriculocystocisternostomy in order to evaluate the long-term outcomes.

Patients and methods

Operative and postoperative data were retrospectively reviewed for six patients harboring suprasellar arachnoid cysts. Imaging was then used to follow success of surgical intervention.

Results

Six patients with suprasellar arachnoid cysts underwent ventriculocystocisternostomy. Presenting symptoms were headaches in three patients, developmental delay in another, and an incidental finding in the remaining patients. All patients had enlarged lateral and third ventricles on initial imaging. Average age at presentation was 145.7 months (65.4–250.2). Follow-up was an average of 46.5 months (3–84). The average cyst size was 153.96 cm³ (42.98–369.20) preoperatively and an average of 39.92 cm³ (3.20–101.47) at follow-up.

Conclusions

Based on our experience, suprasellar arachnoid cyst treatment with ventriculocystocisternostomy is an adequate surgical intervention. Suprasellar and third ventricular size does respond to the surgical intervention at long-term follow-up.     

Analysis of switching insurance plan type. Comparison of two statistical methods

PURPOSE: To compare results of 2 statistical methods for identifying factors in claims data that are associated with switching insurance plans between managed care (MC) and indemnity (IN).METHODS: Using claims data from 2 insurance providers in a northeastern city, we analyzed patients aged 18+ with diabetes, asthma, or congestive heart failure (CHF) who were covered any time in 1993-1997 (N = 88,917). Stratifying by initial plan type, we examined predictors of switching from the initial plan type using logistic regression and survival analysis. Covariates included age, time in study (for logistic models), gender, diabetes (yes/no), CHF (yes/no), and asthma (yes/no). Survival analysis accounted for time to switch and allowed time-varying covariates.RESULTS: In logistic regression models, older individuals who were in IN were much less likely to switch into MC. Those in MC were more likely to switch to IN, with the greatest likelihood of switching in ages 60-69 (OR = 4.00, 95% CI = 3.32-4.83). Females were less likely to switch from IN to MC (OR = 0.92, 95% CI = 0.87-0.98), CHF patients were less likely to switch from IN to MC (OR = 0.75, 95% CI = 0.68-0.83), and diabetes patients were less likely to switch from MC to IN (OR = 0.77, 95% CI = 0.62-0.96). Hazard ratios calculated using Cox regression were similar to odds ratios for most covariates. However, some coefficients for diseases were significant in Cox models but not in the logistic models. Cox models took 45 times longer in CPU time than logistic regression models.CONCLUSIONS: Logistic regression was a good approximation to Cox regression in identifying many of the factors in switching insurance plan in these data, at a fraction of the computing time. However, Cox models allowed diseases to be time-varying, and so was more sensitive to identifying significant relationships with disease.     

Acquired convergence of hormone signaling in breast cancer: ER and PR transition from functionally distinct in normal breast to predictors of metastatic disease

Cumulative exposure to estrogen (E) and progesterone (P) over the menstrual cycle significantly influences the risk of developing breast cancer. Despite the dogma that PR in the breast merely serves as a marker of an active estrogen receptor (ER), and as an inhibitor of the proliferative actions of E, it is now clear that in the breast P increases proliferation independently of E action. We show here that the progesterone receptor (PR) and ER are expressed in different epithelial populations, and target non-overlapping pathways in the normal human breast. In breast cancer, PR becomes highly correlated with ER, and this convergence is associated with signaling pathways predictive of disease metastasis. These data challenge the established paradigm that ER and PR function co-operatively in normal breast, and have significant implications not only for our understanding of normal breast biology, but also for diagnosis, prognosis and/or treatment options in breast cancer patients.